Hyperphosphatemia Clinical Trials

12 recruitingLast updated: June 18, 2026

There are 12 actively recruiting hyperphosphatemia clinical trials across 12 countries. Studies span Phase 3, Phase 2, Not Applicable. Top locations include Tokyo, Japan, Dalton, Georgia, United States, Beijing, Beijing Municipality, China. Updated daily from ClinicalTrials.gov.


Hyperphosphatemia Trials at a Glance

12 actively recruiting trials for hyperphosphatemia are listed on ClinicalTrialsFinder across 6 cities in 12 countries. The largest study group is Phase 3 with 5 trials, with the heaviest enrollment activity in Tokyo, Dalton, and Beijing. Lead sponsors running hyperphosphatemia studies include Taisho Pharmaceutical Co., Ltd., Kyowa Kirin Korea Co., Ltd., and Genzyme Corporation, USA.

Browse hyperphosphatemia trials by phase

Treatments under study

About Hyperphosphatemia Clinical Trials

Looking for clinical trials for Hyperphosphatemia? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hyperphosphatemia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hyperphosphatemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 2

A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia

End Stage Renal Disease on DialysisHyperphosphatemiaChronic Kidney Disease Requiring Chronic Dialysis
R1 Therapeutics168 enrolled26 locationsNCT06712654
Recruiting
Phase 3

A Clinical Study of TS-172 in Hyperphosphatemia Patients on Peritoneal Dialysis

Hyperphosphatemia Patients on Peritoneal Dialysis
Taisho Pharmaceutical Co., Ltd.30 enrolled1 locationNCT07548853
Recruiting
Phase 3

A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

Hyperphosphatemia Patients on Hemodialysis
Taisho Pharmaceutical Co., Ltd.30 enrolled1 locationNCT07548840
Recruiting
Phase 3

A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders

Hyperphosphatemia Patients on Hemodialysis
Taisho Pharmaceutical Co., Ltd.100 enrolled1 locationNCT07285291
Recruiting

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Heart FailurePainInsomnia+22 more
Duke University5,000 enrolled51 locationsNCT04278404
Recruiting
Phase 3

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

HyperphosphatemiaDialysisChronic Kidney Disease, Receiving Dialysis+1 more
Alebund Pharmaceuticals264 enrolled42 locationsNCT06933472
Recruiting
Phase 3

A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

Hyperphosphatemia Patients on Hemodialysis
Taisho Pharmaceutical Co., Ltd.300 enrolled1 locationNCT07285304
Recruiting
Not Applicable

Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

Kidney Failure, ChronicHyperphosphatemia
The University of Queensland3,600 enrolled115 locationsNCT03573089
Recruiting
Phase 2

Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia

Hyperphosphatemia
Jemincare50 enrolled2 locationsNCT06664125
Recruiting

Post Marketing Surveillance Study to Observe Safety and Effectiveness of NEPHOXIL ® in S. Korea Patients

Hyperphosphatemia
Kyowa Kirin Korea Co., Ltd.600 enrolled1 locationNCT06186934
Recruiting

Multicenter, Open, Prospective, 48 Weeks, Observational Study ,Evaluate the Safety and Efficacy of Nephoxil Capsule

Hyperphosphatemia
Kyowa Kirin Korea Co., Ltd.100 enrolled1 locationNCT06206135
Recruiting

An Open Label, Dose Titration Study Of Sevelamer Carbonate Dosed Three Times A Day In Hyperphosphatemic Chronic Kidney Disease (CKD) Patients Not On Dialysis

Hyperphosphatemia in CKD Patients not on Dialysis
Genzyme Corporation, USA40 enrolled1 locationACTRN12606000380594